Evidence map›Paper›PMID 39588767›Full record

ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2025

The Consortium for Clarity in ADRD Research Through Imaging (CLARiTI).

Elizabeth C Mormino, Sarah A Biber, Annalise Rahman-Filipiak, Konstantinos Arfanakis, Lindsay Clark, Jeffrey L Dage, John A Detre, Bradford C Dickerson, Michael C Donohue, Steven Kecskemeti and 14 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Calibration of multisite raters for prospective visual reads of amyloid PET scans.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  4. The National Alzheimer's Coordinating Center (NACC) 1999-2025: Personal history and recollections.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  5. Tau mediates the impact of amyloid and vascular disease burden on the trajectory of clinical symptoms.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  6. Return of research results across the Alzheimer's Disease Research Centers network.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  7. Article
  8. Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  9. Article
  10. Article
  11. The Consortium for Clarity in ADRD Research Through Imaging (CLARiTI).Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Elizabeth C MorminoDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California, USA.ORCID 0000-0002-4542-6537
Sarah A BiberNational Alzheimer's Coordinating Center, University of Washington, Seattle, Washington, USA.
Annalise Rahman-FilipiakDepartment of Psychiatry, University of Michigan, Ann Arbor, Michigan, USA.
Konstantinos ArfanakisDepartment of Biomedical Engineering, Illinois Tech, Chicago, Illinois, USA.
Lindsay ClarkDepartment of Medicine, University of Wisconsin School of Medicine and Public Health, Health Sciences Learning Center, Madison, Wisconsin, USA.
Jeffrey L DageDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
John A DetreDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Bradford C DickersonDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Michael C DonohueDepartment of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Steven KecskemetiDepartment of Medicine, University of Wisconsin School of Medicine and Public Health, Health Sciences Learning Center, Madison, Wisconsin, USA.
Timothy J HohmanDepartment of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
William J JagustDepartment of Epidemiology, School of Public Health, University of California, Berkeley, California, USA.
Dirk C KeeneDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
Walter KukullNational Alzheimer's Coordinating Center, University of Washington, Seattle, Washington, USA.
Swati R LevendovszkyDepartment of Radiology, University of Washington, Seattle, Washington, USA.
Howie RosenDepartment of Neurology, University of California, San Francisco, California, USA.
Paul M ThompsonDepartment of Ophthalmology, Psychiatry and the Behavioral Sciences, Radiology, Psychiatry, and Engineering, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Victor L VillemagneDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
David A WolkDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Ozioma C OkonkwoDepartment of Medicine, University of Wisconsin School of Medicine and Public Health, Health Sciences Learning Center, Madison, Wisconsin, USA.
Gil D RabinvoviciDepartment of Neurology, University of California, San Francisco, California, USA.
Monica Rivera-MindtDepartment of Psychology, Fordham University, Bronx, New York, USA.
Tatiana ForoudDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Sterling C JohnsonDepartment of Medicine, University of Wisconsin School of Medicine and Public Health, Health Sciences Learning Center, Madison, Wisconsin, USA.

Funding

ADRC Consortium for Clarity in ADRD Research Through ImagingU01AG082350 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Sarah Biber, BRADFORD C DICKERSON · 2023 to 2026
$90.0M
National Alzheimer's Coordinating CenterU24AG072122 · NIA · UNIVERSITY OF WASHINGTON · PI STEPHENS, KARI A · 2021 to 2025
$45.8M
Research Education ComponentP30AG072979 · NIA · UNIVERSITY OF PENNSYLVANIA · PI DAVID A WOLK · 2021 to 2026
$24.8M
Improving the sensitivity and specificity of MRI-based biomarkers in Alzheimer's diseaseR01AG069474 · NIA · UNIVERSITY OF PENNSYLVANIA · PI WOLK, DAVID A, YUSHKEVICH, PAUL A. · 2024 to 2025
$1.4M
NIA NIH HHS P30 AG072979NIA NIH HHS R01 AG069474NIA NIH HHS U01 AG082350NIA NIH HHS U24 AG072122NIH HHS U01-AG082350
6 · The paper itself

Abstract

The presence of multiple pathologies is the largest predictor of dementia. A major gap in the field is the in vivo detection of mixed pathologies and their antecedents. The Alzheimer's Disease Research Centers (ADRCs) are uniquely positioned to address this gap. The ADRCs longitudinally follow ≈ 17,000 participants, ranging from cognitively unimpaired to dementia, arising from Alzheimer's disease (AD) and related dementias (ADRD; e.g., AD, Lewy body disorders, vascular). Motivated by the Alzheimer's Disease Neuroimaging Initiative's (ADNI) impact, the ADRC Consortium for Clarity in ADRD Research Through Imaging (CLARiTI) was formed. Leveraging existing ADRC infrastructure, CLARiTI will integrate standardized imaging and plasma collection to characterize mixed pathologies and use community-engaged research methods to ensure that ≥ 25% of the sample is from underrepresented populations (e.g., ethnoculturally minoritized, low education). The resulting ADRD profiles, within a more diverse sample, will provide key resources for ADRCs and an unprecedented, more generalizable publicly available imaging-plasma dataset. HIGHLIGHTS: In vivo detection of mixed pathologies is critical for Alzheimer's disease and related dementias research. The Alzheimer's Disease Research Centers (ADRCs) are uniquely positioned to address gaps related to mixed pathologies. The ADRC Consortium for Clarity in ADRD Research Through Imaging (CLARiTI) will enhance this national program by adding standardized imaging and plasma collection to existing ADRC infrastructure. This effort will provide key resources for ADRCs and an unprecedented publicly available imaging-plasma-neuropath dataset.

Indexed as

Alzheimer DiseaseBrainDementiaNeuroimagingBiomedical ResearchHumansLongitudinal StudiesAlzheimer's diseasebiomarkersmagnetic resonance imagingneuroimagingpathologyplasma markerspositron emission tomography

Identifiers

PMID39588767
PMCPMC11772703

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.